Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy.

Barriers Communication HCP Insulin Type 2 diabetes

Journal

Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025

Informations de publication

Date de publication:
Feb 2023
Historique:
received: 15 06 2022
accepted: 25 10 2022
pubmed: 16 12 2022
medline: 16 12 2022
entrez: 15 12 2022
Statut: ppublish

Résumé

Type 2 diabetes (T2D) progresses over time, and to achieve and maintain adequate glucose control, many people eventually require injectable therapies such as insulin. However, there can be significant barriers to the initiation of these medications, both from people living with T2D and from healthcare practitioners (HCPs). Misconceptions and misinformation relating to the potential risks and benefits of injectable therapies are common and can contribute to negative perceptions regarding their use. Additionally, HCPs are often unaware of the emotional burden associated with T2D. In particular, diabetes distress is a key contributory factor that needs to be addressed to alleviate fears before diabetes education can be successful. The onus is often on the HCP to initiate effective, individualized communication with each patient and make that person feel an active and equal participant in the management of their T2D. Shared decision-making has been demonstrated to improve understanding of the pathophysiology and treatment options, to increase risk awareness, adherence, and persistence, and to improve self-management behaviors (e.g., exercise, self-care) and patient satisfaction. While therapeutic inertia can result from both patient and HCP, HCPs need to bear the responsibility for escalating therapy when necessary. A proactive approach by the HCP, combined with shared decision-making and a patient-centric approach, are important for optimal T2D management; therefore, an open and effective relationship between the HCP and the person living with T2D is essential. This article is written by a person with T2D, a nurse practitioner/Certified Diabetes Care and Education Specialist, and a clinical endocrinologist, with the goal of providing a holistic view of the management experience, exploring patient needs and expectations, recognizing and avoiding HCP and patient barriers, and providing practical advice to HCPs to empower patients who would benefit from injectable therapy.Infographic and video abstract available for this article. Type 2 diabetes can be managed with diet, exercise, and medicines. As type 2 diabetes progresses, the most effective treatment may change, and people may need to start taking insulin or other injections to manage their blood sugar. However, many people do not receive the information needed to understand why their type 2 diabetes has progressed or why they need to change treatment. Also, they may have received inaccurate information about the risks and benefits of insulin injections. The demands of managing type 2 diabetes can have an emotional impact (known as diabetes distress), which can lead to anxiety and make people reluctant to engage in their own care or start new medications. Healthcare professionals need to recognize the impact of diabetes distress so that they can help people with type 2 diabetes overcome these barriers. Understanding the factors driving the behaviors of people with type 2 diabetes and encouraging them to ask questions can help them overcome concerns about changing treatment. This is most likely to be achieved when people with diabetes are actively involved in treatment decisions. This article, written by a person with type 2 diabetes and two healthcare professionals, aims to provide practical guidance for healthcare professionals to recognize the emotional impact of diabetes, and to understand how this affects a person’s ability to manage their condition. This article also provides advice on how to improve communication with patients and to provide effective diabetes education to meet the needs of people living with type 2 diabetes. In this video, the authors, a person with T2D, a nurse practitioner/certified diabetes care and education specialist, and a clinical endocrinologist, provide practical guidance for healthcare professionals. They focus on how to recognize the emotional impact of diabetes, understand how this affects a person’s ability to manage their condition, how to improve communication with patients, and how to provide effective diabetes education to meet the needs of people living with type 2 diabetes, with an emphasis on the initiation and use of injectable therapy.

Autres résumés

Type: plain-language-summary (eng)
Type 2 diabetes can be managed with diet, exercise, and medicines. As type 2 diabetes progresses, the most effective treatment may change, and people may need to start taking insulin or other injections to manage their blood sugar. However, many people do not receive the information needed to understand why their type 2 diabetes has progressed or why they need to change treatment. Also, they may have received inaccurate information about the risks and benefits of insulin injections. The demands of managing type 2 diabetes can have an emotional impact (known as diabetes distress), which can lead to anxiety and make people reluctant to engage in their own care or start new medications. Healthcare professionals need to recognize the impact of diabetes distress so that they can help people with type 2 diabetes overcome these barriers. Understanding the factors driving the behaviors of people with type 2 diabetes and encouraging them to ask questions can help them overcome concerns about changing treatment. This is most likely to be achieved when people with diabetes are actively involved in treatment decisions. This article, written by a person with type 2 diabetes and two healthcare professionals, aims to provide practical guidance for healthcare professionals to recognize the emotional impact of diabetes, and to understand how this affects a person’s ability to manage their condition. This article also provides advice on how to improve communication with patients and to provide effective diabetes education to meet the needs of people living with type 2 diabetes. In this video, the authors, a person with T2D, a nurse practitioner/certified diabetes care and education specialist, and a clinical endocrinologist, provide practical guidance for healthcare professionals. They focus on how to recognize the emotional impact of diabetes, understand how this affects a person’s ability to manage their condition, how to improve communication with patients, and how to provide effective diabetes education to meet the needs of people living with type 2 diabetes, with an emphasis on the initiation and use of injectable therapy.

Identifiants

pubmed: 36520406
doi: 10.1007/s13300-022-01330-z
pii: 10.1007/s13300-022-01330-z
pmc: PMC9943835
doi:

Types de publication

Journal Article

Langues

eng

Pagination

425-446

Subventions

Organisme : NIDDK NIH HHS
ID : K12 DK133995
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Curr Opin Psychiatry. 2019 Sep;32(5):416-421
pubmed: 31135489
Diabetes Educ. 2006 Jun;32 Suppl 4:146S-152S
pubmed: 16831818
J Immigr Minor Health. 2016 Dec;18(6):1413-1422
pubmed: 26660485
Diabetes Obes Metab. 2018 Nov;20(11):2690-2694
pubmed: 29923298
QJM. 2007 Jun;100(6):345-50
pubmed: 17504861
J Oncol Pract. 2008 Sep;4(5):249-253
pubmed: 29452527
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Diabetes Technol Ther. 2016 Oct;18(10):644-649
pubmed: 27541872
Endocrinol Nutr. 2014 Oct;61(8):426-33
pubmed: 24853553
JAMA. 2021 Jun 8;325(22):2262-2272
pubmed: 34077499
Mayo Clin Proc. 2016 Sep;91(9):1231-55
pubmed: 27594187
Sci Adv. 2021 Dec 17;7(51):eabj2836
pubmed: 34919437
Diabetes Obes Metab. 2020 Nov;22(11):1995-2003
pubmed: 32538550
Front Endocrinol (Lausanne). 2018 May 29;9:261
pubmed: 29896155
Medicine (Baltimore). 2020 Aug 7;99(32):e21389
pubmed: 32769870
J Manag Care Spec Pharm. 2022 Sep;28(9):958-968
pubmed: 36001104
Diabetes Care. 2013 Nov;36(11):3411-7
pubmed: 23877982
Clin Diabetes. 2019 Jul;37(3):227-233
pubmed: 31371853
Med Care. 2009 Aug;47(8):823-5
pubmed: 19584758
BMJ Open. 2013 Nov 18;3(11):e003384
pubmed: 24247325
BMJ. 2007 Sep 8;335(7618):493
pubmed: 17761996
Diabetes Metab Syndr Obes. 2014 Mar 06;7:85-94
pubmed: 24623984
Diabet Med. 2013 May;30(5):512-24
pubmed: 23323988
Diabetes Ther. 2017 Apr;8(2):221-226
pubmed: 28260218
Patient Educ Couns. 2009 Mar;74(3):295-301
pubmed: 19150199
Patient. 2014;7(4):437-50
pubmed: 24958464
Diabetes Ther. 2017 Dec;8(6):1309-1318
pubmed: 29027634
Health Qual Life Outcomes. 2018 Apr 23;16(1):71
pubmed: 29685153
Diabetes Obes Metab. 2006 Jul;8(4):419-28
pubmed: 16776749
Diabetes Res Clin Pract. 2017 Apr;126:248-253
pubmed: 28288434
Ther Adv Endocrinol Metab. 2019 May 03;10:2042018819844694
pubmed: 31105931
Telemed J E Health. 2009 Nov;15(9):830-9
pubmed: 19919189
Diabetes Obes Metab. 2018 Jan;20(1):103-112
pubmed: 28656746
PLoS One. 2015 Sep 18;10(9):e0136202
pubmed: 26383535
Patient Educ Couns. 2017 Dec;100(12):2159-2171
pubmed: 28693922
Diabetes Educ. 2012 Jan-Feb;38(1):67-76
pubmed: 22127677
Diabetes Care. 2022 Jan 1;45(Suppl 1):S1-S2
pubmed: 34964812
Diabetes Ther. 2019 Apr;10(2):437-449
pubmed: 30850934
Diabetes Obes Metab. 2017 May;19(5):672-681
pubmed: 28058769
Patient Educ Couns. 2014 Sep;96(3):281-6
pubmed: 25034637
Diabetologia. 2006 Feb;49(2):271-8
pubmed: 16362814
Endocrine. 2015 Feb;48(1):14-24
pubmed: 24927794
BMJ. 2004 Jun 12;328(7453):E303-4
pubmed: 15191997
Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93
pubmed: 25190523
Diabetes Ther. 2020 Jan;11(1):305-318
pubmed: 31848983
Diabetes Res Clin Pract. 2011 Aug;93 Suppl 1:S97-9
pubmed: 21864760
J Diabetes Sci Technol. 2011 May 01;5(3):723-30
pubmed: 21722588
JBI Database System Rev Implement Rep. 2016 Jan;14(1):210-47
pubmed: 26878928
Diabet Med. 2014 Jul;31(7):764-72
pubmed: 24606397
Diabetes Care. 2013 Aug;36 Suppl 2:S127-38
pubmed: 23882037
Lancet Diabetes Endocrinol. 2016 Aug;4(8):706-716
pubmed: 26915314
Diabetes Ther. 2019 Apr;10(2):341-366
pubmed: 30815830
Diab Vasc Dis Res. 2017 May;14(3):172-183
pubmed: 28467203
Diabetes Care. 2013 Oct;36(10):3054-61
pubmed: 23949558
Diabetes Care. 2005 Mar;28(3):626-31
pubmed: 15735199
Curr Diab Rep. 2015 Dec;15(12):112
pubmed: 26458383
Rev Diabet Stud. 2020;16:46-50
pubmed: 33905473
Patient Educ Couns. 2014 Mar;94(3):417-22
pubmed: 24341962
Adv Ther. 2017 Sep;34(9):2083-2092
pubmed: 28779282
Am Fam Physician. 2013 Jan 1;87(1):48-54
pubmed: 23317025
Diabetes Obes Metab. 2020 Nov;22(11):2004-2012
pubmed: 32729217
J Med Ethics. 2006 Sep;32(9):507-10
pubmed: 16943329
Diabetes Care. 2019 Mar;42(3):349-351
pubmed: 30787057
Ann Intern Med. 2017 Sep 19;167(6):365-374
pubmed: 28828487
Diabet Med. 2016 Jun;33(6):742-51
pubmed: 27105298
J Diabetes Res. 2016;2016:2830910
pubmed: 26682229
Diabetes Spectr. 2020 Feb;33(1):8-15
pubmed: 32116448
Diabet Med. 2019 Jul;36(7):803-812
pubmed: 30985025
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Int J Clin Pract. 2021 Apr;75(4):e13921
pubmed: 33336836
Diabetes Care. 2019 Aug;42(8):1593-1603
pubmed: 31177185
Adv Ther. 2018 Nov;35(11):1735-1745
pubmed: 30374807
Diabetes Care. 2016 Nov;39(11):2026-2035
pubmed: 27527848
Drugs. 2015 Apr;75(6):577-87
pubmed: 25851098

Auteurs

Schafer Boeder (S)

Division of Endocrinology and Metabolism, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla, CA, USA. sboeder@health.ucsd.edu.

David Matamoros (D)

, Phoenix, USA.

Caroline Mansy (C)

Delmarva Diabetes Center, Salisbury, MD, USA.

Classifications MeSH